Answers are grounded in this paper and cite their sources.
Progress in neurology frequently lags 10 to 20 years behind that of cardiology.Early data correlating cardiovascular disease and serum levels of total and low-density lipoprotein cholesterol have led to treatments (exercise, weight loss, and statins) which have decreased age-adjusted cardiovascular mortality rates by 40%.In this regard, serum cholesterol levels have transitioned from a biomarker to a risk factor as treatment aimed at lowering serum levels have conferred clinical benefits.For 25 years, neurologists have been trying to apply this model to Alzheimer disease (AD) with little success.3][4][5][6] Because Aβ42 was elevated in plasma in asymptomatic first-degree relatives of patients with presenilin 1, presenilin2, and amyloid precursor protein mutations who had early onset AD (EOAD), they reasoned that Aβ42 levels might also be elevated in asymptomatic firstdegree relatives of patients with late onset AD (LOAD).The Jacksonville Mayo group compared plasma Aβ42 levels between two cohorts of relatives of patients with AD and two groups of controls.The first cohort consisted of 103 first-degree relatives of patients with LOAD and 106 unrelated controls, the second of 109 subjects from 25 multigenerational LOAD families and 50 married-in spouses.In both cohorts, the relatives were between 20 and 65 years of age and cognitively normal.In both cohorts, small but significant differences between relatives and controls were found.However, there are several important caveats.First, the absolute magnitude of the differences was small.Second, measurements of Aβ42 required substantial normalization, and comparisons of absolute values across different assay batches were not possible.Indeed, the absolute value in family members in one study was virtually the same as that of controls in a second study.Third, although the Mayo group showed only modest variation in Aβ42 levels on a time scale of hours or days, substantial increases occur with normal aging after the age of 65.In terms of predictive value in individual family members, the utility of Aβ42 remains to be demonstrated.Among patients with dementia and clinical Alzheimer disease, plasma Aβ42 levels are lower than normal, suggesting that plasma levels gradually decline from elevated levels through normal levels to low level as patients transition from cognitively normal with increased genetic risk through MCI and into clinical dementia.Thus to be clinically useful, clinicians would need to do long term tracking of Aβ42 levels.
No takes yet. Share an insight, caveat, or question.
Crystal et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: